Sparsha Pharma to expand mfg base

Sparsha Pharma International Private Limited, India’s first WHO-certified Fentanyl Transdermal Patch manufacturing company, is planning to expand the manufacturing base at its Hyderabad facility.

“We will expand our current manufacturing facility at Medchal with an investment of Rs 35-40 crore. Construction work will start in three months,” Dange Veerapaneni, managing director, Sparsha Pharma, said.

Launching two new drugs — Artho-Touch and Diclo-Touch transdermal patches — for pain management, Veerapaneni said the market potential of these two products in India would be Rs 5-10 crore in a year’s time. “We aim to market these products in non-regulatory countries including Ukraine and Malaysia.”

 

The two new-generation transdermal patches would benefit patients suffering from tennis elbow, chronic form of arthritis, peritendinitis (swelling of tendons), pain after trauma, shoulder blade pain, neck pain, etc.